
SER Stock Forecast & Price Target
SER Analyst Ratings
Bulls say
Serina Therapeutics Inc. is well-positioned for future growth, particularly with its pipeline candidate SER-270, which has the potential to drive significant long-term upside beyond current forecasts. The company’s innovative POZ Platform delivery technology enhances drug precision and addresses the limitations of existing biocompatible polymers, increasing the attractiveness of its product candidates. Additionally, the expanding approval landscape for the enFuse delivery system indicates a favorable trajectory for SER-252, bolstering the overall positive outlook for the company's future performance.
Bears say
Serina Therapeutics reported a consistent net loss of $0.64 per share, raising concerns about its financial sustainability amidst ongoing development efforts. The company faces several risks, including potential delays in advancing its lead drug candidate, SER-252, through clinical assessment, as well as challenges in securing regulatory approval and commercial success due to competitive pressures. Furthermore, the downward revision of the company's full-year 2025 net loss forecast to $2.01 per share, up from an initial estimate of $0.36, highlights deteriorating financial prospects and increasing risks of dilution.
This aggregate rating is based on analysts' research of Serina Therapeutics, Inc. and is not a guaranteed prediction by Public.com or investment advice.
SER Analyst Forecast & Price Prediction
Start investing in SER
Order type
Buy in
Order amount
Est. shares
0 shares